Nexavar
What Nexavar is used for
Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Differentiated thyroid carcinoma Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Nexavar
- Active substance
- sorafenib
- Disease area
- Carcinoma, Hepatocellular; Carcinoma, Renal Cell
- Medicine group
- Antineoplastic agents
- ATC code
- L01EX02
- Marketing authorisation holder
- Bayer AG
- Authorised in the EU since
- 2006
Official information
In the USA
Same active substance: Nexavar
In India
- Sorafenib: 8 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Nexavar used for?
Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Differentiated thyroid carcinoma Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
What is the active substance in Nexavar?
Nexavar contains sorafenib.
Who makes Nexavar?
The EU marketing authorisation holder is Bayer AG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU